
Featured
The $2 Million Genome: How the 2026 CRISPR Approval Rewrites Medical Economics
The 2026 FDA approval of an in vivo CRISPR therapy for Sanfilippo syndrome marks a historic shift in genomic medicine, yet introduces severe health ec...
Read Full Story →